Title: Risk factors for severe outcomes of COVID-19: a rapid review

**Authors:** Aireen Wingert, Jennifer Pillay, Michelle Gates, Samantha Guitard, Sholeh Rahman, Andrew Beck, Ben Vandermeer, Lisa Hartling

- Aireen Wingert (corresponding), Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta (Project Coordinator), <a href="mailto:awingert@ualberta.ca">awingert@ualberta.ca</a>
- Jennifer Pillay, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta Edmonton Clinic Health Academy, 11405-87 Avenue NW, Edmonton, Alberta, Canada T6G 1C9 (Research Project Coordinator), jpillay@ualberta.ca
- Michelle Gates, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta (Project Coordinator), <a href="mailto:mgates1@ualberta.ca">mgates1@ualberta.ca</a>
- Samantha Guitard, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta (Research Assistant), <a href="mailto:guitard@ualberta.ca">guitard@ualberta.ca</a>
- Sholeh Rahman, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta (Research Assistant), sholeh1@ualberta.ca
- Andrew Beck, Alberta Research Centre for Health Evidence (Research Assistant), <a href="mailto:abeck@ohri.on.ca">abeck@ohri.on.ca</a>
  Ben Vandermeer, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta (Biostatistician), <a href="mailto:bv1@ualberta.ca">bv1@ualberta.ca</a>
- Lisa Hartling, Director, Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, hartling@ualberta.ca

## Contributor and guarantor information:

AW, JP, AB, BV and LH contributed to the conception and design of the study. AW, JP, SG, SR, AB, and BV contributed to the screening of eligible studies. AW, SG, SR, and AB contributed to the acquisition of data. AW, JP, MG, BV and LH contributed to the synthesis and interpretation of data. AW, JP, MG, drafted the manuscript. AW, JP, MG, SG, SR, AB, BV, and LH revised the manuscript for important intellectual content. All authors approved the manuscript for submission.

Competing interests declaration: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare: grants from the National Advisory Committee for Immunization during the conduct of the study; no other relationships or activities that could appear to have influenced the submitted work. LH is supported by a Canada Research Chair in Knowledge Synthesis and Translation.

**Data sharing statement:** All data used in this review are available within the manuscript and accompanying supplemental files.

Word count (main text): 3,858

### **ABSTRACT: 399 words**

**Background:** Identification of high-risk groups is needed to inform COVID-19 vaccine prioritization strategies in Canada. A rapid review was conducted to determine the magnitude of association between potential risk factors and risk of severe outcomes of COVID-19.

Methods: Methods, inclusion criteria, and outcomes were prespecified in a protocol that is publicly available. Ovid MEDLINE(R) ALL, Epistemonikos COVID-19 in L·OVE Platform, and McMaster COVID-19 Evidence Alerts, and select websites were searched to 15 June 2020. Studies needed to be conducted in Organisation for Economic Co-operation and Development countries and have used multivariate analyses to adjust for potential confounders. After piloting, screening, data extraction, and quality appraisal were all performed by a single reviewer. Authors collaborated to synthesize the findings narratively and appraise the certainty of the evidence for each risk factor-outcome association. Results: Of 3,740 unique records identified, 34 were included in the review. The studies included median 596 (range 44 to 418,794) participants with a mean age between 42 and 84 years. Half of the studies (17/34) were conducted in the United States and 19/34 (56%) were rated as good quality. There was low or moderate certainty evidence for a large (≥2-fold) association with increased risk of hospitalization in people having confirmed COVID-19, for the following risk factors: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age over 45 years (vs. younger), male gender, Black race/ethnicity (vs. non-Hispanic white), homelessness, and low income (vs. above average). Age over 60 and 70 years may be associated with large increases in the rate of mechanical ventilation and severe disease, respectively. For mortality, a large association with increased risk may exist for liver disease, Bangladeshi ethnicity (vs. British white), age over 45 years (vs. <45 years), age over 80 years (vs. 65-69 years), and male gender in those 20-64 years (but not older). Associations with hospitalization and mortality may be very large (≥5-fold increased risk) for those aged over 60 years.

**Conclusion:** Among other factors, increasing age (especially >60 years) appears to be the most important risk factor for severe outcomes among those with COVID-19. There is a need for high quality primary research (accounting for multiple confounders) to better understand the level of risk that might be associated with immigration or refugee status, religion or belief system, social capital, substance use disorders, pregnancy, Indigenous identity, living with a disability, and differing levels of risk among children.

PROSPERO registration: CRD42020198001

# What is already known

- The novel nature of COVID-19 means that in many countries there are currently no pre-determined priority groups for the receipt of the eventual COVID-19 vaccine(s).
- Primary research is rapidly emerging, but consensus on who might be at increased risk of severe outcomes from COVID-19 has not been established.

# What this study adds

- This rapid review shows that advancing age (≥45 years and especially ≥60 years) may be the most important risk factor for hospitalization and mortality from COVID-19.
- Other important risk factors for severe disease identified by this review include several pre-existing chronic conditions (class III obesity, heart failure, diabetes, chronic kidney disease, liver disease, dementia), male gender, Blackrace/ethnicity (vs. non-Hispanic white), Bangladeshi ethnicity (vs. British white), low income (vs. high), and homelessness.

## **INTRODUCTION**

Novel coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the newly identified Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),[1] which reached worldwide pandemic status in early March 2020.[2] As of August 24, there were over 23 million confirmed cases worldwide and 800,000 deaths attributed to the virus.[3] Most people who develop COVID-19 will experience mild-to-moderate illness primarily affecting the respiratory system and recover at home.[4] In more severe cases, patients may require specialized care (e.g., admission to hospital and/or intensive care unit [ICU], assisted ventilation)[5] as the disease can progress to respiratory failure and/or affect multiple organ systems.[4] Though new primary research is emerging rapidly, the evidence is fragmented and consensus on who might be at increased risk of severe outcomes from COVID-19 has not been established.

Given the rapid spread of COVID-19 since its first emergence in late 2019, and potential for severe illness (including death), the development of a preventive vaccine has become a global priority. [6] COVID-19 vaccine development has been progressing at an unprecedented pace. Once a successful COVID-19 vaccine candidate becomes available, the initial vaccine supply is not expected to be sufficient to cover the entire population right away. Therefore, there is an urgent need to plan for the efficient, effective, and equitable allocation of eventual COVID-19 vaccines when limited initial vaccine supply will necessitate recommendations for the vaccination of certain groups earlier than others. Due to the novel nature of COVID-19, these groups for early vaccination have not yet been established. [7]

The National Advisory Committee on Immunization (NACI) is an expert advisory body that provides advice on the use of vaccines in Canada. [8] At the time of writing, NACI is developing interim guidance on priority pandemic immunization strategies for COVID-19 vaccination when initial vaccine supply is limited. [7] To inform this guidance, NACI is using its recently published Ethics, Equity, Feasibility and Acceptability (EEFA) Framework[9] to ensure these factors are systematically and comprehensively considered. One of the evidence informed tools that make up this framework is the "Equity Matrix" which has adapted the PROGRESS-Plus model of health determinants and outcomes [10] to ensure important vaccine-specific equity factors are explicitly included. The resulting "P²ROGRESS And Other Factors" framework includes a range of biological and social factors that likely contribute to inequities in health outcomes across population groups, but it is not yet clear how each factor might apply to COVID-19 outcomes. A discussion on the use of this Equity Matrix, with evidence from this rapid review, as a critical tool to guide the ethically just allocation of scarce resources is published elsewhere. [11]

With the aim of providing timely, evidence-informed guidance on pandemic vaccine prioritization, NACI required a rigorous and expedited synthesis of the available evidence on population groups who are at increased risk of severe illness and mortality as a result of COVID-19. Responding to this need, we conducted a rapid review to determine the magnitude of association between "P²ROGRESS And Other Factors" and risk of severe outcomes of COVID-19.

METHODS Review Approach The urgent need for empiric evidence to inform the prioritization of pandemic immunization strategies in Canada necessitated a rapid but rigorous approach to synthesizing the currently available data. Therefore, we performed a rapid review informed by traditional systematic review methodology, [12] with several modifications to allow for the evidence to be synthesized on an expedited timeline (e.g., single reviewer for study selection, data extraction, and assessment of risk of bias) and focusing on studies having high applicability to Canada (e.g., countries with universal health care system)

NACI's High Consequence Infectious Disease Vaccine Working Group was consulted to develop and refine the scope of the review (i.e., priority population(s), risk condition(s)/factor(s), and outcomes of interest), but was not involved in the conduct of the review. The working group was not involved in selection of studies nor the synthesis of findings.

The review was conducted following an *a-priori* protocol (PROSPERO #CRD42020198001). Because there is not yet formal guidance on the reporting of rapid reviews, reporting adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[13]

### Literature Search

A health sciences librarian searched Ovid MEDLINE(R) ALL on 15 June 2020 using concepts related to COVID-19, P²ROGRESS And Other Factors, and severe outcomes (Supplemental File). The search was limited to studies published in English or French in 2020. Additionally, the search was limited to populations in countries that are members of the Organisation for Economic Cooperation and Development (OECD), [14] in an effort to include studies of highest relevance to the Canadian context. Editorials and letters were excluded. We supplemented the Medline search by hand-searching Epistemonikos COVID-19 in L·OVE Platform (<a href="https://app.iloveevidence.com/topics">https://app.iloveevidence.com/topics</a>) and McMaster COVID-19 Evidence Alerts (<a href="https://plus.mcmaster.ca/COVID-19/">https://plus.mcmaster.ca/COVID-19/</a>) for relevant prognosis or aetiology studies up to 12 June 2020. A hand-search of relevant websites recommended by the NACI working group was also undertaken, as well as continual surveillance for publication of eligible pre-prints located by the search. Searches were exported to an Endnote Library (X9, Clarivate Analytics, Philadelphia, PA) and duplicates removed.

### **Eligibility Criteria**

We included studies published in English or French since 1 January 2020 that reported on the magnitude of association between potential P²ROGRESS And Other Factors and severe outcomes of COVID-19 (Supplemental File). Eligible populations, in order of priority, were people (a) from a general/community sample, (b) with COVID-19 confirmed (by laboratory testing or epidemiologic linkage), (c) hospitalized with COVID-19, and d) with a risk factor of interest. To ensure relevance to the Canadian context, studies had to be conducted in OECD countries; [14] we included studies from countries that do not provide universal (or near universal) coverage for core medical services (i.e., Chile, Greece, Mexico, Poland, the Slovak Republic, and the United States) [15] but considered these to be less applicable to the Canadian context when interpreting the findings.

The exposures of interest were any P²ROGRESS And Other Factors believed to be associated with differential health outcomes across population groups (i.e., pre-existing conditions, place or state of residence, race/ethnicity/culture/language, immigration, refugee status, occupation, gender identity or sex, religion or belief system, education or literacy level, socioeconomic status, social capital, age, and other factors). [16, 17] Eligible comparators were population groups that did not have the P²ROGRESS And Other Factor, or experienced a P²ROGRESS And Other Factor to a different degree (e.g., older vs. younger). Factors could be present among a population with or without COVID-19. The infection must have been confirmed by laboratory testing or linked epidemiologically (e.g., household contact). Studies including populations with other pandemic-related infections (e.g., Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome) were excluded if data specific to COVID-19 cases could not be isolated. We also excluded studies of interventions and where the entire study population had severe disease (e.g., ICU settings).

Any length of follow-up for outcomes of interest was acceptable. Eligible studies reported on at least one primary outcome (i.e., rate of hospitalization, hospital length of stay, severe disease [as defined by study authors; for example, composite outcome of ICU transfer or death], ICU admission and length of stay, need for mechanical ventilation [MV], and mortality [case fatality or all-cause]). In order to prioritize the most rigorous and applicable evidence, we included only prospective and retrospective cohort studies that employed a multivariate analysis and provided results of the independent contribution of P<sup>2</sup>ROGRESS And Other Factors to severe outcomes, while accounting for potential confounders (minimally age and sex). Pre-prints were included only if they were accepted by a peer-reviewed journal; pre-prints that were later published (between the date of the search and manuscript submission) were included. Government reports from hand-searched websites were eligible.

### **Study Selection**

All records retrieved by the searches were exported to a Microsoft Office Excel (Microsoft Corporation, Redmond, WA) spreadsheet for screening. After piloting the eligibility criteria on a sample of 70 records, one reviewer independently screened records for inclusion by title/abstract, and those deemed to be potentially relevant were assessed by full text. Uncertainties about the inclusion of any full text study were resolved through consultation with a second reviewer.

#### **Data Extraction**

Following a pilot round, one reviewer independently extracted data from each included study into an Excel workbook. We extracted data on (a) population size and demographics, (b) setting, (c) dates of data collection, (d) COVID-19 ascertainment method, (e) co-infections, (f) outcomes reported with definitions for composite outcomes (e.g., severe disease), (f) number of participants analysed, (h) relevant outcome data related to P²ROGRESS factors of interest. For both continuous and dichotomous outcomes, we extracted adjusted relative effect sizes (i.e., odds ratio [OR], risk ratio [RR], hazard ratio [HR]) and measures of variability (95% confidence interval [CI]). A second reviewer was consulted in the event of uncertainty about any of the extracted data. Given the expedited approach, we extracted only data that were reported within the included studies and made no attempt to contact authors for missing or unclear data.

## **Quality Assessments**

To expedite quality assessments, we did not use a formal tool; instead we focused on key variables that were considered to be most relevant to the topic, and that would allow for meaningful stratification of studies by quality. The key variables that we used to assess the quality of the included studies were (a) the extent of adjustment for relevant covariates (i.e., basic adjustment for age and sex, versus more extensive adjustment for numerous potential confounders including comorbidities), (b) follow-up duration and extent of censorship for some outcomes (e.g.,  $\geq 2$  weeks for mortality), and (c) inappropriate or large exclusions from the study and/or analysis (e.g., missing data on risk factor status or analytical variables). Following assessment of these key variables by a single reviewer, studies without concerns for all three criteria were rated good while others were rated fair. A second reviewer was consulted in the case of uncertainty about the assessment of any individual study.

### **Synthesis**

Given substantial clinical (e.g., risk factors and/or comparators examined, outcome definitions) and methodological (varying covariates included in the adjusted analyses, different measures of association) heterogeneity, it was not appropriate to pool the studies statistically. Instead, we present a narrative summary of the results across studies for each risk factor. When making conclusions about the association between a  $P^2ROGRESS$  And Other Factor and an outcome, we focused primarily on the magnitude of effect rather than statistical significance, which is heavily dependent on sample size. We categorized associations to be small/unimportant (odds ratio [OR] or risk ratio  $[RR] \le 1.70$ ), moderate (1.71 to 1.99), large ( $\ge 2.00$ ), or very large ( $\ge 5.00$ ). [18] When determining the magnitude, we compared findings across all relevant studies and often relied heavily on the findings of the largest and/or good quality studies.

#### **Certainty of Evidence**

The expedited approach to evidence synthesis did not allow for a formal appraisal of the certainty of evidence across studies for each P²ROGRESS And Other Factor-Outcome association. Instead, a single reviewer assessed the certainty of the evidence for each association considering relevant components of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach: [19, 20] (a) directness in terms of country (presence of universal healthcare) and source population (community sample vs. hospitalized patients), (b) sample size (n<500 considered small) and magnitude of association, (c) study quality, and (d) consistency of associations (in direction and magnitude) across studies. Bodies of evidence started at high certainty[21] and were rated down for weaknesses in any of the aforementioned characteristics. The level of certainty in associations are referred to using the terms 'uncertain' (no or very low certainty), 'may' (low or some certainty), and 'probably' (moderate certainty). [22] At least two other reviewers confirmed the certainty of evidence appraisals, with disagreements resolved by discussion.

#### **RESULTS**

**Characteristics of Studies** 

Of 3,740 unique records identified by the searches, 949 were screened at full text, and 34 studies that reported on 32 unique populations were included in the review (Figure 1; Supplemental File shows studies excluded by full text, with reasons). [23-56] Three studies conducted in the United Kingdom (UK)[39, 44, 47] used overlapping cohorts from a single medical/research database, and were considered as a single population in the analysis. Another large UK study[56] is likely to also be overlapping with these populations, but the degree of overlap is not known.




Figure 1. PRISMAflow of study selection

Table 1 shows the characteristics of the included studies (full details about individual studies in Supplemental File). Briefly, all of the included studies were prospective or retrospective cohorts. The studies were published between 23 April and 6 July 2020, and half (17/34, 50%) reported on populations in the United States. [23, 24, 31, 32, 36-38, 40-43, 45, 46, 49, 51, 53, 54] The remaining countries represented (Italy, [25, 27-30, 35, 50, 55] Spain, [26] UK[33, 39, 44, 47, 48, 52, 56]) all have universal or universal-like healthcare (one study used data from 17 countries). All studies reported on adults, and the overall median was 596 participants (range 44 to 418,794). The mean or median age of the populations studied ranged from 42 to 84 years (32/34 [94%] 54 to 71 years). Most studies (16/34, 47%) examined the association between risk factors and outcomes in a hospitalized population. Studies most commonly reported on the independent association of pre-existing conditions (n=27 studies), gender identity or sex (n=18), and race or ethnicity (n=12) with severe outcomes (most commonly hospitalization, n=9). P<sup>2</sup>ROGRESS And Other Factors not examined in the included studies were immigration or refugee status,

religion or belief system, social capital, and substance use disorders. There were also no data specific to pregnant women, indigenous populations, people with disabilities, nor different ages in children.

**Table 1. I**ncluded studies overview (n=34)

(no. of studies)   (no. of studies)   (no. of studies)   (no. of studies)	,	(no of studios*)			Risk of bias
Retrospective cohort (25) Prospective cohort (9) Country: USA (17) Italy (8) UK (7 studies in 5 populations) Spain (1) Multi-country <sup>§</sup> (1) Multi-country <sup>§</sup> (1) Multi-country <sup>§</sup> (1)  Multi-country <sup>§</sup> (1)  Respiratory (asthma, COPD, chronic bronchitis, lung disease, previous pneumonia) (8 studies of 10 populations) Renal (chronic kidney disease) (5) Neurological (dabetes, hyperglycemia) (8) Respiratory (asthma, COPD, chronic bronchitis, lung disease, previous pneumonia) (8 studies of 7 populations) Renal (chronic kidney disease) (5) Neurological (dabetes, hyperglycemia) (8) Renal (chronic kidney disease) (5) Neurological (dabetes) (4) Hepatic (liver disease, with or without cirrhosis) (3) Immunocompromised (rheumatic disease, HIV/AIDS) (2) Sastrointestinal (irritable bow el disease) (1) Race of residence (4) Race or ethnicity (11 studies of 10 populations) Cocupation (1) Scoceoconoric status (5 studies of 1 populations) Education (1) Scoceoconoric status (5 studies of 4 populations) Age (17 studies of 16 populations) Age (17 studies of 16 populations) Age (17 studies of 16 populations)  Ration (25) Lab-confirmed (5) Lab-confirmed or story (1) Lab-confirmed or stream or sever disease (2) Lab-confirmed or stream or symptoms (1)  Retro Codes (1) Lab-confirmed or stream or symptoms (1)  Lab-confirmed or stream or sever disease (2) Lab-confirmed or stream or symptoms (1)  Retro Codes (1) Lab-confirmed (5) Lab-confirmed (5) Lab-confirmed (7) Lab-confirmed (8) Lab-confirmed (8) Lab-confirmed (8) Lab-confirmed (8) Lab-confirmed (8) Lab-confirmed (8) Lab-confirmed (9) Lab-confirmed (8) Lab-confirmed (9) Lab-confir	Ctudy docions	,	(no. of studies)	(no. of studies*)	(no. of studies)
<ul> <li>Smoking status (7 studies of 5 populations)</li> <li>Alcohol consumption (3 studies of 1 population)</li> </ul>	<ul> <li>Retrospective cohort (25)</li> <li>Prospective cohort (9)</li> <li>Country:</li> <li>USA (17)</li> <li>Italy (8)</li> <li>UK (7 studies in 5 populations)</li> <li>Spain (1)</li> </ul>	<ul> <li>Pre-existing disease/disability:         <ul> <li>Any comorbidity or number of comorbidities (4)</li> <li>Underw eight, overw eight or obesity (12 studies of 10 populations)</li> <li>Cardiovascular (chronic cardiac disease/heart disease, congestive heart failure, coronary artery disease, hyperlipidemia, hypertension) (10 studies of 9 populations)</li> <li>Endocrinologic (diabetes, hyperglycemia) (8)</li> <li>Respiratory (asthma, COPD, chronic bronchitis, lung disease, previous pneumonia) (8 studies of 7 populations)</li> <li>Renal (chronic kidney disease) (5)</li> <li>Malignancy (cancer) (5)</li> <li>Neurological (Alzheimer's, dementia, chronic neurological disorder) (4)</li> <li>Hepatic (liver disease, with or without cirrhosis) (3)</li> <li>Immunocompromised (rheumatic disease, HIV/AIDS) (2)</li> <li>Mental health (2)</li> <li>Gastrointestinal (irritable bow el disease) (1)</li> </ul> </li> <li>Place of residence (4)</li> <li>Race or ethnicity (11 studies of 10 populations)</li> <li>Occupation (1)</li> <li>Gender identity or sex (18 studies of 17 populations)</li> <li>Education (1)</li> <li>Socioeconomic status (5 studies of 4 populations)</li> <li>Age (17 studies of 16 populations)</li> <li>Other factors:</li></ul>	Diagnosis:  RT-PCR/PCR (25)  Lab-confirmed (5)  ICD codes (1)  Lab-confirmed or ICD codes (2)  Lab-confirmed or	<ul> <li>Rate of hospitalization (9)</li> <li>Hospitalization/self-isolation (composite) (1)</li> <li>Hospital length of stay (0)</li> <li>Severe disease (4)</li> <li>ICU admission (3)</li> <li>ICU length of stay (0)</li> <li>ICU or MV (1)</li> <li>Non-invasive ventilation or MV (1)</li> <li>MV (4)</li> <li>ICU or mortality (composite) (3)</li> <li>MV or mortality (composite) (1)</li> </ul>	Good (19)

<sup>\*</sup> a study may contribute to more than one risk group, or outcome

<sup>§</sup> study of healthcare workers includes data from Australia, Canada, Chile, China, Germany, India, Ireland, Italy, Netherlands, New Zealand, Pakistan, Poland, Singapore, South Africa, Sweden, UK, and USA

BMI: body massindex; COVID-19: novel coronavirus; HIV/AIDS: humanimmunodeficiency virus/acquired immunodeficiency syndrome; ICD: International Classification of Diseases; ICU: intensive care unit; MV: mechanical ventilation; No: number; NR: not reported; RT-PCR; reverse transcription polymerase chain reaction; UK: United Kingdom; USA: United States of America

## **Study Quality**

The majority of studies (19/34, 56%) were rated as good quality [23, 24, 29, 31, 33-36, 40, 42, 45, 46, 48-53, 55] because they adjusted for age, sex, and pre-existing disease in their analysis, had adequate follow-up of outcomes, and few or no missing data. The remaining studies had flaws in one or more of the three domains that we considered to be most important for this review.

## **Association Between Risk Factors and Outcomes**

Table 2 shows a summary of findings for associations between each reported risk factor and outcomes of interest; all contributing data are shown in the Supplemental File.

Table 2. Summary of evidence for associations between risk factors and severe outcomes of COVID-19

		Magnitude of association (confidence in association) <sup>c</sup> , by outcome					
Risk factor (at-risk vs. reference population) <sup>a</sup>	Population <sup>b</sup>	Magnitude of associations are shown as: uncertain (no/very low confidence), no important association (-; OR or RR ≤1.70), moderate association (+; 1.71-1.99), large/important association (+++; ≥5.00)					
		Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Pre-existing conditions							
Body mass index(kg/m²)d	•						
Underweight (<18.5) vs. normal (18.5-24.9)	Hospitalized		- (low)	- (low)		- (low)	
Overweight (25.0-29.9) vs. normal	Community sample or positive for COVID-19	- (low)	uncertain	uncertain	- (low)	- (low)	
Obesity class I and II (≥30.0) vs. normal	Community sample or positive for COVID-19	+ (low)	+ (low)	+ (low)	- (low)	- (moderate)	
Obesity class III (≥40.0) vs. normal	Positive for COVID-19	++ (low)		uncertain	+ (low)	- to + (low)	
Respiratory conditions							
Chronic, varied (e.g., asthma, COPD)	Community sample or positive for COVID-19	- (moderate)	uncertain	uncertain	- (moderate)	- (moderate)	
Prior pneumonia	Community sample	- (low)					
Cardiova scular di sea se							
Heart failure	Community sample	- (low)					
ribuit failuit	Positive for COVID-19	++ (low)			+ (low)	- (low)	
Coronary artery disease, hypertension, hyperlipidemia, composite outcomes	Community sample or positive for COVID-19	- (moderate)	uncertain	uncertain	- (low)	- (low)	
Diabetes	Community sample	- (low)					
Diabetes	Positive for COVID-19	++ (low)	uncertain	- (low)	- (low)	- (moderate)	
Liver diese se	Positive for COVID-19	- (low)				++ (low)	
Liver disease	Hospitalized					- (low)	
Chronic kidney disease	Community sample or positive for COVID-19	++ (moderate)			- (moderate)	(moderate)	
Inflammatory bowel disease	Positive for COVID-19	- (low)			- (low)		
Dementia/chronic neurologic disorders							

		Magnitu	ide of associatio	n (confidence in a	association) <sup>c</sup> , by out	come	
Risk factor (at-risk vs. reference population) <sup>a</sup>	Population <sup>b</sup>	Magnitude of associations are shown as: uncertain (no/very low confidence), no important association (-; OR or RR ≤1.70), moderate association (+; 1.71-1.99), large/important association (+++; ≥2.00), or very large important association (+++; ≥5.00)					
		Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Alzheimer's disease or dementia	Community sample	++ (low)				- (low)	
Chronic neurologic disorders	Hospitalized					- (low)	
Cancer	•					,	
Any cancer	Positive for COVID-19	- (moderate)			- (moderate)	- (moderate)	
Hematological malignancy	Positive for COVID-19					+ (low)	
Immunocompromised							
Rheumatic disease	Positive for COVID-19	uncertain	uncertain			uncertain	
Human immunodeficiency virus	Hospitalized					uncertain	
Mental health		_					
Depression	Positive for COVID-19	(low)					
Ever visited a psychiatrist	Community sample	- (low)					
Other factors							
Age <sup>d</sup>	T						
45-54 vs.≤45 years old	Positive for COVID-19	++ (moderate)			- (low)	++ (low)	
50-64 vs.≤45 years old	Positive for COVID-19	++ (moderate)			- (low)	++ (moderate)	
>60 vs. ≤45 years old	Positive for COVID-19	++/+++ (moderate/low)		++ (low)	+ (low)	++/+++ (moderate/low)	
>70 or 75 vs. ≤45 years old	Positive for COVID-19	+++ (moderate)			++ (low)	+++ (moderate)	
>80 vs. ≤45 years old	Positive for COVID-19	+++ (low)				+++ (low)	
70-79 vs. 65-69 years old	Hospitalized					- (moderate)	
>80 vs. 65-69 years old	Hospitalized					++ (low)	
Increased age (continuous/incremental) <sup>e</sup>	Community sample or positive for COVID-19	Approximately 2-6% relative increase per year (moderate)	- (low)	- (low)	- (low)	Approximately 5-10% relative increase per year	

Risk factor	<b>Demulation</b> b	Magnitude of association (confidence in association) <sup>c</sup> , by outcome  Magnitude of associations are shown as: uncertain (no/very low confidence), no important						
(at-risk vs. reference population) <sup>a</sup>	Population <sup>b</sup>	association (-; OR or RR ≤1.70), moderate association (+; 1.71-1.99), large/important association (+++; ≥2.00), or very large important association (+++; ≥5.00)						
		Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality		
						(moderate)		
Gender or sex								
Male vs.female (all ages, mean 54 to 73)	Community sample	- (low)						
ivale vs. remaie (all ages, mean 54 to 75)	Positive for COVID-19	++ (moderate)	uncertain	+ (low)	- (low)	- (moderate)		
Male vs.female (20-64 years) <sup>f</sup>	Hospitalized					++ (low)		
Race/ethnicity					•			
Black vs. non-Hispanic white	Community sample or positive for COVID-19	++ (low)	- (moderate)	- (moderate)	- (moderate)	- (moderate)		
Hispanic vs. non-Hispanic white	Positive for COVID-19	- (low)	uncertain	- (low)	- (low)			
Asian vs. w hite	Community sample or positive for COVID-19	- (moderate)	- (low)	- (low)	- (low)	- (moderate)		
Asian (Bangladeshi) vs. British white	Hospitalized					++ (low)		
Culture/language/immigrant/refugee status								
Place of residence/household size								
Living in a low income area	Positive for COVID-19	- (low)						
Homeless vs. has a home	Positive for COVID-19	++ (low)						
Suburban vs. urban hospital	Hospitalized			uncertain				
1, 3, or 4 vs. 2 household members	Community sample	- (low)						
Occupation								
Laryngologist or intubator vs. assistant	Healthcare workers for COVID-19 patients	- (low)						
Education level								
Low er education vs. university degree	Community sample	- (low)						
Socioeconomic status								

		Magnitude of association (confidence in association) <sup>c</sup> , by outcome  Magnitude of associations are shown as: uncertain (no/very low confidence), no important association (-; OR or RR ≤1.70), moderate association (+; 1.71-1.99), large/important association (++; ≥2.00), or very large important association (++; ≥5.00)					
Risk factor (at-risk vs. reference population) <sup>a</sup>	Population <sup>b</sup>						
		Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Highest vs. low est quintile of social deprivation	Community sample	+ (low)				- (moderate)	
Income ≤25 <sup>th</sup> vs. >50 <sup>th</sup> or 75 <sup>th</sup> percentile	Positive for COVID-19	++ (low)					
≥Average vs. below average income	Community sample	- (low)					
Smoking							
Current or former vs. never	Community sample or positive for COVID-19	- (moderate)		uncertain	- (low)	- (low)	
Alcohol consumption							
Above vs. w ithin guidelines	Community sample or positive for COVID-19	- (low)					
Physical activity level							
Below vs. w ithin guidelines	Community sample or positive for COVID-19	(low)					

COPD: chronic obstructive pulmonary disease; ICU: intensive care unit; OR: odds ratio; RR: risk ratio

<sup>&</sup>lt;sup>a</sup> When not listed, the reference group are those without the risk factor.

<sup>&</sup>lt;sup>b</sup> Outcomes of severe disease (as defined by authors), ICU admission, mechanical ventilation, and mortality are all in a hospitalized population, except for Liver Disease, where findings differed depending on the population denominator used.

<sup>&</sup>lt;sup>c</sup> A formal assessment of the quality/confidence of the evidence was not performed but was informed by the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. We determined our confidence in the magnitude of the associations by considering primarily study limitations (risk of bias), consistency in findings across studies, and precision (sample size). Very low confidence indicates that were have no/very low confidence about possible associations; low means that the evidence indicates that there *may* be an association; moderate means that the evidence indicates that there *probably* is an association. High certainty evidence as not found for any association.

<sup>&</sup>lt;sup>d</sup> For categorical data for age, and BMI, the reference group differed slightly across studies.

<sup>&</sup>lt;sup>e</sup> For continuous or incremental data for age, the rate of hospitalization and mortality outcomes, approximately half of the studies analyzed data on a continuum (with the remainder reporting in incremental categories, e.g., 5-year units)

f Subgroup data from one study that analyzed the younger population separately

There was low or moderate certainty of evidence for important/large associations with increased risk of hospitalization in people having confirmed COVID-19, for the following risk factors: obesity class III (body mass index ≥40 kg/m²; 1 study, n=5,297), [49] heart failure (2 studies, n=6,331), [23, 49] diabetes (2 studies, n=6,331), [23, 49] chronic kidney disease (confirmed COVID-19 or community sample; 2 studies, n=424,073), [47, 49] dementia (1 study, n=418,794), [47] age over 45 years (vs. 45 or younger; 2 studies, n=6,331), [23, 49] male gender (3 studies, n=3,812), [23, 49, 51] black race/ethnicity (vs. non-Hispanic white; confirmed COVID-19 and community samples, 5 studies in 4 populations, n=428,606), [23, 44, 47, 49, 51] homelessness (1 study, n=1,052), [23] and low income (<25<sup>th</sup> vs. >50<sup>th</sup> percentile; 1 study, n=1,052). [23] Age over 60 and over 70 years may be associated with important increases in the rate of mechanical ventilation (1 study, n=486)[40] and severe disease (1 study, n=2,725), [49] respectively.

For mortality, important associations with increased risk may exist for liver disease (2 studies, n=20,597),[33,53] Bangladeshi ethnicity (vs. British white; 1 study, n=130,091),[56] and age over 45 years (vs. <45 years; 3 studies, n=87,819). [33, 49, 56] The data were somewhat inconsistent for gender, with most studies showing moderate certainty of no important effect, but one large fair quality study (n=130,091)[56] from the UK that stratified its analysis by age showed that hospitalized males aged 20-64 years (but not older) may be at about two-fold increased risk of mortality compared to females. Associations with hospitalization and mortality may be very large for those aged over 60 years (2 studies, n=6,331 for hospitalization; [23, 49] 3 studies, n=24,163 for mortality [33, 41, 49]) and are probably very large for those over 70 years (2 studies, n=6,331 for hospitalization; [23, 49] 2 studies, n=22,858 for mortality[33, 49]). One study (n=63,094)[56] directly compared subgroups of older adults, showing that compared to those aged 65-69 years, there may be no important increased risk of mortality among hospitalized adults aged 70-79 years, but risk may increase about 2-fold for those 80 years and older. Studies treating age on a continuum or across small increments consistently found that risks for hospitalization and mortality increased with increasing age (e.g., approximately 2-6% and 5-10% relative increase in risk per year) (3 studies in 2 populations, n=422,275 for hospitalization; [44, 47, 51] 11 studies, n=6,877 for mortality). [25-27, 31, 35, 38, 45, 46, 48, 51, 55]

Moderate associations may exist for increased risk of mechanical ventilation (4 studies, n=1,559) [38, 40, 42, 46] and ICU admission (2 studies, n=873), [38, 42] and severe disease (1 study, n=2,725)[49] with obesity (body mass index  $\geq 30$  or 40 kg/m²); severe disease with heart failure (1 study, n=2,725); [49] mortality with haematological malignancy (1 study, n=1,183); [52] mechanical ventilation with male gender (4 studies, n=881); [27, 40, 42, 46] and hospitalization with social deprivation (highest vs. lowest quintile; 1 study, n=340,996). [44]

There was moderate certainty evidence for no important increase in risk of hospitalization with chronic respiratory conditions (4 studies in 3 populations, n=425,125), [23, 44, 47, 49] cardiovascular disease apart from heart failure (i.e., coronary artery disease, hypertension, hyperlipidaemia; 4 studies in 3 populations, n=425,125), [23, 44, 47, 49] non-specific cancer (2 studies, n=6,331), [23, 49] Asian race/ethnicity other than Bangladeshi (vs. non-Hispanic white; 3 studies in 2 populations, n=424,073), [44, 47, 49] and current or former smoking (5 studies in 3 populations, n=425,125). [23, 39, 44, 47, 49] Additionally, there was moderate certainty evidence for no important increase in severe

disease with chronic respiratory conditions (1 study, n=2,725), [49] chronic kidney disease (2 studies, n=2,922), [24, 49] nonspecific cancer (2 studies, n=2,769), [29, 49] and Black race/ethnicity (vs. non-Hispanic white; 2 studies, n=3,030); [36, 49] and no important increase in risk of mortality with obesity (body mass index  $\geq 30$  kg/m²; 6 studies, n=8,716), [35, 38, 43, 46, 49, 51] chronic respiratory conditions (4 studies, n=23,315), [31, 33, 46, 49] diabetes (4 studies, n=23,315), [31, 33, 46, 49] chronic kidney disease (3 studies, n=23,058), nonspecific cancer (3 studies, n=24,041), [33, 49, 52] male gender (9 studies, n=27,875), [25-27, 31, 33, 35, 46, 49, 51] Black (5 studies, n=135,418)[38, 48, 49, 51, 56] or Asian race/ethnicity (vs. non-Hispanic white; 3 studies, n=4,015), [38, 48, 49] and social deprivation (lowest vs. highest quintile; 1 study, n=130,091). [56] Overall, there were few data for the ICU and mechanical ventilation outcomes.

### **DISCUSSION**

Responding to an urgent need for empiric evidence to inform decision-making on Canada's immunization strategies, [7] in this rapid review we synthesized studies employing a multivariate analysis to ascertain potential independent associations between "P²ROGRESS And Other Factors" and severe outcomes of COVID-19. Among 22 potential risk factors examined across the included studies, the most important risk factors (i.e., those associated with large/important increased risk; OR or RR ≥2.0) for hospitalization among those with confirmed COVID-19 were several pre-existing chronic health conditions (obesity class III, heart failure, diabetes, chronic kidney disease [community sample or with COVID-19], dementia [community sample]), older age (>45 years vs. younger), male gender, Black race/ethnicity (community sample or with COVID-19), homelessness, and low income (≤25th vs. >50th percentile). Liver disease may be associated with a large increased risk of mortality among people with COVID-19 and advancing age (>45 years vs. younger) and Bangladeshi ethnicity (vs. British white) are likely to be associated with a large increased risk of mortality among hospitalized patients. There is evidence to suggest that male gender may increase risk of mortality among younger (20-64 years), but not older men.

Among the factors identified as increasing risk of severe outcomes, age seemed to be the most influential; adults older than 60 years may have at least 5 times increased odds of hospitalization and mortality from COVID-19 compared to those aged less than 45 years. This increased risk appears to magnify at least to some degree even for those older than 60 years, with those aged over 80 years having double the mortality risk of those aged 65-69 years. Though we focused the review on better quality studies that minimally controlled for age and sex, the strength of certain associations should be interpreted cautiously because there are likely to be multiple unmeasured confounders that have not been accounted for. For example, studies reporting on associations between outcomes and age did not adjust for nursing home residency, and studies examining race did not account for occupation, which may be an important confounder influencing susceptibility to the infection. [56] In addition, it is important to be aware that criteria for COVID-19 testing and hospitalization may differ by place and time, but it is difficult to predict how this may have impacted the findings. In general, many studies conducted testing based on symptoms and the evidence is likely most applicable to these populations. The evidence for mechanical ventilation, ICU admission, and severe disease outcomes was relatively sparse, and we located no evidence meeting our publication date and inclusion criteria to inform the

impact of immigration or refugee status, religion or belief system, social capital, substance abuse disorders, pregnancy, indigenous identity, living with a disability, nor differing levels of risk among children in various age groups.

The findings of this rapid review will be used to populate the Equity Matrix of NACI's Ethics, Equity, Feasibility, and Acceptability Framework, [9] which will be a part of a suite of considerations for informing the development of NACI recommendations on priority pandemic immunization strategies when initial COVID-19 vaccine supply is limited. NACI will be using the results of this rapid review and their current understanding of the epidemiology of COVID-19 in Canada to identify distinct inequities associated with COVID-19, potential reasons for these inequities, and suggested interventions to reduce inequities and improve access to vaccine when it becomes available. The Equity Matrix applied to COVID-19 with evidence to-date can be found elsewhere.[11]

## Strengths and Limitations

The expedited methods used in this review allowed for a rapid but comprehensive synthesis of the highest quality evidence available on multiple risk factors associated with severe COVID-19 outcomes that is applicable to OECD countries. Generalizations to other countries should be made with caution, as high risk groups in these populations may differ. We excluded studies only examining patients with severe COVID-19 (i.e., in ICU settings), and therefore our findings for mechanical ventilation and mortality are applicable to people with COVID-19 or in general populations, but not necessarily all those with severe infection. Most studies of patients in the ICU setting that we located were relatively small and descriptive in nature, such that many would have been excluded due to lack of adjustment or only have been able to provide low or very low certainty evidence due to their lack of precision. As described previously, many available studies do not control for any important confounding variables which limited the number of studies and risk factors included in this review. Given the rapid emergence of new evidence on the topic, potential associations (or lack of association) for which only low or very low certainty of evidence is available should continue to be reviewed as new primary research is published. There is a need for high quality primary research (accounting for multiple confounders) to better understand the level of risk that might be associated with immigration or refugee status, religion or belief system, social capital, substance abuse disorders, pregnancy, indigenous identity, living with a disability, and differing levels of risk among children in various age groups.

## **FIGURES**

Figure 1 – PRISMA flow of study selection

#### **ACKNOWLEDGMENTS**

We would like to thank the National Advisory Committee on Immunization (NACI) High Consequence Infectious Disease Vaccine Working Group (Caroline Quach, Shelley Deeks, Yen Bui, Kathleen Dooling, Robyn Harrison, Kyla Hildebrand, Michelle Murti, Jesse Papenburg, Robert Pless, Nathan Stall, and Stephen Vaughan) for their contributions to the project. We also thank Liz Dennett (MLIS) for conducting the Medline search, and Karyn Crawford for assisting with article retrieval.

#### **ABBREVIATIONS**

COVID-19 Novel coronavirus disease 2019

ICU Intensive care unit

NACI National Advisory Committee on Immunization

OECD Organisation for Economic Co-operation and Development

OR Odds ratio

P<sup>2</sup>ROGRESS Pre-existing disease or disability, place of residence, race, ethnicity, culture, language,

immigrant/refugee status, occupation, gender, religion/belief system, education,

socioeconomic status, social capital, age, and other factors

RR Risk ratio

### **REFERENCES**

- 1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it 2020. <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (accessed 24 Aug 2020).">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (accessed 24 Aug 2020).</a>
- 2. World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report 51. Geneva, Switzerland: World Health Organization 2020.
- 3. World Helath Organization. Coronavirus disease (COVID-19): Situation report 210. Geneva, Switzerland: World Health Organization 2020.
- 4. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis* 2020;34:101623.
- 5. Government of Canada. Coronavirus disease 2019 (COVID-19): Epidemiology update. Ottawa, Canada: Government of Canada 2020.
- 6. World Health Organization. Accelerating a safe and effective COVID-19 vaccine Geneva, Switzerland: World Health Organization 2020. <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine (accessed 31 July 2020).</a>
- 7. Government of Canada. National Advisory Committee on Immunization (NACI): Membership and representation 2020. <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html">https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html</a> (accessed 24 Aug 2020).
- 8. Government of Canada. Research priorities for COVID-19 vaccines to support public health decisions 2020. <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/research-priorities-covid-19-vaccines.html">https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/research-priorities-covid-19-vaccines.html</a> (accessed 24 Aug 2020).
- 9. Ismail SJ, Hardy K, Tunis M. A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations. *Vaccine* 2020;38(36):5861-76.
- 10. Evans T, Brown H. Road traffic crashes: operationalizing equity in the context of health sector reform. *Inj Control Saf Promot* 2003;10(1-2):11-2.
- 11. Ismail SJ, Tunis MC, Zhao L, et al. Navigating inequities: a roadmap out of the pandemic. Submitted to BMJ. Aug 2020
- 12. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chinchester, UK: John Wiley & Sons 2019.
- 13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.

- 14. Organisation for Economic Cooperation and Development. Member countries 2020. https://www.oecd.org/about/members-and-partners/ (accessed 24 Aug 2020).
- 15. Fraser Institute. Comparing Performance of Universal Health Care Countries, 2019. <a href="https://www.fraserinstitute.org/studies/comparing-performance-of-universal-health-care-countries-2019">https://www.fraserinstitute.org/studies/comparing-performance-of-universal-health-care-countries-2019</a> (accessed 24 Aug 2020).
- 16. O'Neill J, Tabish H, Welch V, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. *J Clin Epidemiol* 2014;67(1):56-64.
- 17. Oliver S, Kavanagh J, Caird J, et al. Health promotion, inequalities and young people's health: a systematic review of research. London, UK: EPPI-Centre, Social Science Research Unit, Institute of Education, University of London 2008.
- 18. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol* 2011;64(12):1311-6.
- 19. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-94.
- 20. Murad MH, Mustafa RA, Schünemann HJ, et al. Rating the certainty in evidence in the absence of a single estimate of effect. *Evid Based Med*. 2017;22(3):85-7.
- 21. Iorio A, Spencer FA, Flavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients, *BMJ* 2015;350:h870.
- 22. Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020;119:126-35.
- 23. Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff (Millwood) 2020:101377hlthaff202000598.
- 24. Bhargava A, Fukushima EA, Levine M, et al. Predictors for severe COVID-19 infection. *Clin Infect Dis* 2020.
- 25. Bianchetti A, Rozzini R, Guerini F, et al. Clinical presentation of COVID19 in dementia patients. j*Jo Nutr Health Aging* 2020;24(6):560-2.
- 26. Borobia AM, Carcas AJ, Arnalich F, et al. a cohort of patients with COVID-19 in a major teaching hospital in Europe. *J Clin Med* 2020;9(6).
- 27. Busetto L, Bettini S, Fabris R, et al. Obesity and COVID-19: an Italian snapshot. *Obesity (Silver Spring)* 2020.
- 28. Cecconi M, Piovani D, Brunetta E, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for COVID-19 infection in Lombardy, Italy. *J Clin Med* 2020;9(5).

- 29. Colaneri M, Sacchi P, Zuccaro V, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. *Euro Surveill* 2020;25(16).
- 30. Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged >= 80 years. *Geriatrics & Gerontology International* 2020.
- 31. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *medRxiv* 2020.
- 32. D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. *Ann Rheum Dis* 2020.
- 33. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *BMJ* (Clin Res Ed) 2020;369:m1985.
- 34. El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: a prospective international multicentre cohort study. *Anaesthesia* 2020.
- 35. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res* 2020;158:104931.
- 36. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 Georgia, March 2020. MMWR Surveill Summ 2020;69(18):545-50.
- 37. Hajifathalian K, Krisko T, Mehta A, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from new york: clinical implications. *Gastroenterol* 2020.
- 38. Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. *Obesity (Silver Spring)* 2020.
- 39. Hamer M, Kivimaki M, Gale CR, et al. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain Behav Immun* 2020.
- 40. Hur K, Price CPE, Gray EL, et al. Factors associated with intubation and prolonged intubation in hospitalized patients with COVID-19. *JAMA Otolaryngol Head Neck Surg* 2020:194599820929640.
- 41. Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. *J Intern Med* 2020.
- 42. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. *Obesity (Silver Spring*) 2020.
- 43. Klang E, Kassim G, Soffer S, et al. Morbid obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. *Obesity (Silver Spring)* 2020.

- 44. Lassale C, Gaye B, Hamer M, et al. Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. *Brain Behav Immun* 2020.
- 45. Okoh AK, Sossou C, Dangayach NS, et al. Coronavirus disease 19 in minority populations of Newark, New Jersey. *Int J Equity Health* 2020;19(1):93.
- 46. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. *Metabolism* 2020;108:154262.
- 47. Patel AP, Paranjpe MD, Kathiresan NP, et al. Race, socioeconomic deprivation, and hospitalization for COVID-19 in english participants of a national biobank. *medRxiv* 2020.
- 48. Perez-Guzman PN, Daunt A, Mukherjee S, et al. Report 17: Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a London NHS Trust: a retrospective cohort study. *Imperial College London* 2020.
- 49. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ (Clin Res Ed)* 2020;369:m1966.
- 50. Piano S, Dalbeni A, Vettore E, et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. *Liv Int* 2020.
- 51. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with covid-19. *NEJM* 2020.
- 52. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. *Br J Haematol* 2020.
- 53. Singh S, Khan A. clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. *Gastroenterol* 2020.
- 54. Singh S, Khan A, Chowdhry M, et al. Risk of severe COVID-19 in patients with inflammatory bowel disease in United States. a multicenter research network study. *Gastroenterol* 2020.
- 55. Violi F, Cangemi R, Romiti GF, et al. Is albumin predictor of mortality in COVID-19? *Antioxid Redox Signal* 2020.
- 56. Public Health England. Disparities in the risk and outcomes of COVID-19. London, UK: Public Health England 2020.